0000000001257585

AUTHOR

E D'amico

showing 4 related works from this author

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…

2015

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…

Genetics and Molecular Biology (all)MaleChronic HepatitisHepacivirusRibavirin/adverse effectsAsthenia/chemically inducedHepacivirusPolyethylene GlycolBiochemistryPolyethylene GlycolsBody Mass IndexChronic Liver Disease0302 clinical medicineNeutropenia/chemically inducedInterferon-alpha/adverse effectsMedicineChroniclcsh:ScienceLiver Diseasesvirus diseasesAntiviral Agents/adverse effectsCohortScience & Technology - Other Topics030211 gastroenterology & hepatologyDrug Therapy CombinationCohort studyHumanmedicine.medical_specialtyAlpha interferonGastroenterology and HepatologyAntiviral AgentsMicrobiologyDose-Response Relationship03 medical and health sciencesPharmacotherapyHepatitis C Chronic/drug therapyDose Prediction MethodsDrug TherapyAnemia/chemically inducedHumansHemoglobinAgedMedicine and health sciencesBiochemistry Genetics and Molecular Biology (all)HepaciviruScience & TechnologyDose-Response Relationship DrugFlaviviruseslcsh:ROrganismsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseaseschemistryAgricultural and Biological Sciences (all)Withholding TreatmentAstheniaImmunologyProportional Hazards Modellcsh:QHuman medicineRNA virusesPhysiologylcsh:MedicinePeginterferon-alfaPolyethylene Glycols/adverse effectsAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Cohort Studieschemistry.chemical_compoundOutcome Assessment Health CareMedicine and Health Sciences030212 general & internal medicineViralPathology and laboratory medicineMultidisciplinarybiologyHepatitis C virusPharmaceuticsMedicine (all)AnemiaHepatitis CHematologyRecombinant ProteinOutcome Assessment (Health Care)/methodsMiddle AgedMedical microbiologyHepatitis CRecombinant ProteinsHost-Pathogen InteractionMultidisciplinary SciencesPhysiological ParametersResearch DesignCombinationHost-Pathogen InteractionsVirusesRNA ViralFemaleDrugPathogensHost-Pathogen Interactions/drug effectsResearch ArticleAdultNeutropeniaClinical Research DesignResearch and Analysis MethodsOutcome Assessment (Health Care)Internal medicineRibavirinRecombinant Proteins/adverse effectsRNA Viral/bloodAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding TreatmentAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Proportional Hazards ModelsAntiviral Agentbusiness.industryRibavirinBody WeightHepacivirus/drug effectsViral pathogensInterferon-alphaHepatitis C Chronicbiology.organism_classificationHepatitis virusesMicrobial pathogensRNAAdverse EventsCohort StudiebusinessPloS one
researchProduct

Giacomo Serpotta e il "pareggiamento delle arti": la decorazione degli oratori fra manipolazione vitalistica e vocazione classicista

2009

ABSTRACT GIACOMO SERPOTTA AND THE “EQUALIZATION OF THE ARTS”: DECORATION OF THE ORATORIES BETWEEN VITALISTIC MANIPULATION AND CLASSICIST VOCATION Ettore Sessa The value of the whole of Giacomo Serpotta's artistic vision in the orchestration of the figu¬rative apparatuses of his oratories was certainly one of the principal primers of his historical-critical raising in the modernist period. In 1901 Mauceri and in 1911 Ricci and Basile heighten a profile of it, however synthetic, of angling and above all of different breath from the rediscovery realized in positivist age. Classifiable, in fact, among the eighteenth century precedents of Gesamtkunstwerk aesthetical plant (according to a rather …

Serpotta decorazione oratoriSettore ICAR/18 - Storia Dell'Architettura
researchProduct

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with differe…

2016

OBJECTIVES: This study aims to evaluate the reliability and clinical utility of NS3 sequencing in hepatitis C virus (HCV) 1-infected patients who were candidates to start a PI-containing regimen. METHODS: NS3 protease sequencing was performed by in-house-developed HCV-1 subtype-specific protocols. Phylogenetic analysis was used to test sequencing reliability and concordance with previous genotype/subtype assignment by commercial genotyping assays. RESULTS: Five hundred and sixty-seven HCV plasma samples with quantifiable HCV-RNA from 326 HCV-infected patients were collected between 2011 and 2014. Overall, the success rate of NS3 sequencing was 88.9%. The success rate between the two subtype…

0301 basic medicinens3Genotyping TechniquesvirusesDrug ResistanceHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyTelaprevirchemistry.chemical_compoundgenotype; genotyping techniques; hepacivirus; hepatitis C; humans; RNA viral; retrospective studies; sequence analysis; DNA; viral nonstructural proteins; drug resistance viral; mutation; pharmacology; infectious diseases0302 clinical medicineRetrospective StudieGenotypePharmacology (medical)ViralGenotype; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; RNA Viral; Retrospective Studies; Sequence Analysis DNA; Viral Nonstructural Proteins; Drug Resistance Viral; MutationProteolytic enzymesvirus diseasesSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis Chcv-rna levelsInfectious DiseasesHCV-RNARNA Viral030211 gastroenterology & hepatologySequence Analysismedicine.drugHumanMicrobiology (medical)medicine.medical_specialtyGenotypeHepatitis C virusConcordanceSettore MED/12 - GASTROENTEROLOGIAGenotype; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; RNA Viral; Retrospective Studies; Sequence Analysis DNA; Viral Nonstructural Proteins; Drug Resistance Viral; Mutation; Pharmacology; Pharmacology (medical); Infectious DiseasesBiology03 medical and health sciencesBoceprevirInternal medicineDrug Resistance ViralmedicinehcvHumansGenotypingGenotyping TechniquesRetrospective StudiesPharmacologyHepaciviruViral Nonstructural ProteinSettore MED/09 - MEDICINA INTERNASequence Analysis DNADNAVirologydigestive system diseases030104 developmental biologychemistrySequence AnalysiMutationRNAGenotyping TechniqueRNA viral
researchProduct

Leggi nascoste tra costruzioni mirabili

2009

Serpotta GiacomoSettore ICAR/18 - Storia Dell'Architettura
researchProduct